Core Activities

Building on our extensive experience in developing vaccines for companion animals, we are now advancing a series of vaccines targeting chronic inflammation in the skin, lungs, and heart. By focusing on cytokines that have been clinically validated by monoclonal antibodies in human treatments, we anticipate a high probability of success, similar to the positive outcomes achieved in companion animals.

Obesity is a major contributor to numerous health issues worldwide. Recently, innovative peptide-based drugs have emerged as powerful tools in combating the obesity epidemic.

However, access to these treatments remains limited for many due to their high costs, largely driven by expensive production processes.

Through advanced molecular modeling, we are developing next-generation vaccines designed to make these potent anti-obesity therapies more affordable and accessible to all.

Aging is an inevitable process, though not classified as a disease. However, extending a healthy lifespan is a core objective of modern medicine. Recent insights reveal that low-level chronic inflammation is a driving force behind aging, offering a unique opportunity to target its origins through vaccination. If the success seen in mouse models translates to humans, these vaccines could become one of the most valuable breakthroughs in biotechnology.

Alzheimer’s disease, a significant threat among the elderly, is a primary focus. DeepVax has designed some of the most promising vaccine candidates preclinically tested to date, with the potential to offer groundbreaking efficacy in combating age-related neurodegeneration.